Business Description
Imunon Inc
NAICS : 325412
SIC : 2834
ISIN : US15117N6022
Description
Imunon Inc is developing new medicines that harness the building blocks of life to work in harmony with the body's immune system. It is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 8.15 | |||||
| Equity-to-Asset | 0.57 | |||||
| Debt-to-Equity | 0.16 | |||||
| Debt-to-EBITDA | -0.06 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 39.6 | |||||
| 3-Year EPS without NRI Growth Rate | 36.6 | |||||
| 3-Year FCF Growth Rate | 33.6 | |||||
| 3-Year Book Growth Rate | -40.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 26.51 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 15.96 | |||||
| 9-Day RSI | 29.72 | |||||
| 14-Day RSI | 37.42 | |||||
| 6-1 Month Momentum % | -19.23 | |||||
| 12-1 Month Momentum % | -6.03 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.3 | |||||
| Quick Ratio | 2.3 | |||||
| Cash Ratio | 1.89 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -51.3 | |||||
| Shareholder Yield % | 23.98 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -187.41 | |||||
| ROA % | -114.45 | |||||
| ROIC % | -688.2 | |||||
| ROC (Joel Greenblatt) % | -958.13 | |||||
| ROCE % | -182.07 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.4 | |||||
| Price-to-Tangible-Book | 1.39 | |||||
| EV-to-EBIT | -0.12 | |||||
| EV-to-Forward-EBIT | -0.08 | |||||
| EV-to-EBITDA | -0.12 | |||||
| EV-to-FCF | -0.13 | |||||
| Price-to-Net-Current-Asset-Value | 1.8 | |||||
| Price-to-Net-Cash | 2.82 | |||||
| Earnings Yield (Greenblatt) % | -833.33 | |||||
| FCF Yield % | -158.46 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Imunon Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.89 | ||
| Beta | 1.32 | ||
| Volatility % | 153.97 | ||
| 14-Day RSI | 37.42 | ||
| 14-Day ATR ($) | 0.016225 | ||
| 20-Day SMA ($) | 0.838819 | ||
| 12-1 Month Momentum % | -6.03 | ||
| 52-Week Range ($) | 0.49428 - 3.634 | ||
| Shares Outstanding (Mil) | 14.5 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Imunon Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Imunon Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Imunon Inc Frequently Asked Questions
What is Imunon Inc(LTS:0HUZ)'s stock price today?
The current price of LTS:0HUZ is $0.79. The 52 week high of LTS:0HUZ is $3.63 and 52 week low is $0.49.
When is next earnings date of Imunon Inc(LTS:0HUZ)?
The next earnings date of Imunon Inc(LTS:0HUZ) is 2025-03-28 Est..
Does Imunon Inc(LTS:0HUZ) pay dividends? If so, how much?
Imunon Inc(LTS:0HUZ) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers